Amid patent expirations, litigation and tariff costs, J&J says it expects more growth ahead, fueled in part by its blood ...

Long-term data suggest Moderna’s personalized melanoma shot provides “durable tumor control,” one analyst said. Elsewhere, ...

While early, the results indicate drugs known as ITK inhibitors have the potential to match or surpass the efficacy observed ...

Four recent deals fueled more angst about China’s biotech progress, while Pfizer, Bristol Myers and Sarepta all worked to ...

The results build on evidence U.S. regulators found so compelling last year they proactively awarded J&J a new kind of drug ...

The “Great Healthcare Plan” is vague, but would send money directly to ACA enrollees and entrench the pricing deals the ...

As with the many other “most-favored-nation” deals between the White House and large pharmas, the agreement is short on ...

More than 3,000 prescriptions were written for Novo’s GLP-1 pill in its first week on the market. Elsewhere, Emergent reached ...

The decision comes months after the FDA had suspended the vaccine’s license. One analyst speculated the company might shelve the product altogether.

AbbVie is paying $650 million for a dual-targeting immunotherapy from China’s RemeGen. Elsewhere, Alnylam missed an earnings ...

Co-founded by Jennifer Doudna and Fyodor Urnov, the company intends to simultaneously develop many gene editing treatments ...

Startups raised $14.2 billion last year, the highest funding total since 2022. Health AI companies collected 54% of total ...